- Title: Subtitle
- Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study
- Creators
- Daniel Pryma - University of PennsylvaniaBennett Chin - Duke UniversityRichard Noto - Rhode Island HospitalJoseph Dillon - University of IowaLilja Solnes - Sidney Kimmel Comprehensive Cancer CenterTheresa White - Progenics PharmaceuticalsNancy Stambler - Progenics PharmaceuticalsTess Lin - Progenics PharmaceuticalsVincent A. DiPippo - Progenics PharmaceuticalsJessica Donato Jensen - Progenics PharmaceuticalsSyed Mahmood - Progenics PharmaceuticalsVivien Wong - Progenics PharmaceuticalsCamilo Jimenez - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.4005-4005
- DOI
- 10.1200/JCO.2018.36.15_suppl.4005
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Internal Medicine; Fraternal Order of Eagles Diabetes Research Center; Endocrinology and Metabolism
- Record Identifier
- 9984361572702771
Abstract
Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study
Journal of clinical oncology, Vol.36(15_suppl), pp.4005-4005
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.4005
Details
Metrics
13 Record Views